Oncology – Lung
RCT | Toripalimab plus chemotherapy for patients with treatment-naive advanced non–small-cell lung cancer.
11 Oct, 2022 | 13:31h | UTC
RCT | Pembrolizumab vs. placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer.
29 Sep, 2022 | 13:22h | UTCPembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC – The ASCO Post
Adjuvant Pembrolizumab Prolongs DFS in Resected Non-Small Cell Lung Cancer – Cancer Therapy Advisor
Commentary on Twitter
New Research in @TheLancetOncol—Pembrolizumab improves disease-free survival vs placebo in completely resected, PD-L1-unselected, stage IB–IIIA #NSCLC
From Prof Mary O’Brien & colleagues https://t.co/Azqb8WTOwp pic.twitter.com/141bhAPtg5
— The Lancet Respiratory Medicine (@LancetRespirMed) September 13, 2022
RCT | First-Line Serplulimab vs. placebo added to chemotherapy in patients with extensive-stage small cell lung cancer.
28 Sep, 2022 | 13:41h | UTCEffect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
RCT | Efficacy and safety of carboplatin with nab-paclitaxel vs. docetaxel in older patients with squamous non-small-cell lung cancer.
14 Sep, 2022 | 13:00h | UTC
Commentary on Twitter
New research: in a ph3 RCT pts aged 70 yrs and older with squamous non-small-cell #lungcancer, overall survival was significantly longer with #carboplatin & nab-paclitaxel vs #docetaxel
👉https://t.co/qOuaVpO61f pic.twitter.com/TSnMguOkoR— The Lancet Healthy Longevity (@LancetLongevity) December 9, 2021
RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.
13 Sep, 2022 | 13:22h | UTCEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)
Commentary on Twitter
Our phase III randomized study, published in Lancet Oncology today, showed high-dose steroid didn’t improve SOB and should not be used routinely in pts with lung ca for SOB palliation. My personal link in Lancet Oncology article ⁰https://t.co/Mj0AAzMujB pic.twitter.com/FMG7csHZsn
— Joe Y Chang (@JoeChangMD) September 7, 2022
RCT | Anatomical segmentectomy vs. standard lobectomy for non-small cell lung cancer up to 2 cm.
6 Sep, 2022 | 14:28h | UTCRelated:
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.
29 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
Results from EMPOWER-Lung 3 demonstrate increased overall survival with #cemiplimab plus platinum-doublet #chemotherapy compared with cemiplimab as first-line treatment in patients with advanced non-small cell #LungCancer, irrespective of #PD-L1 expressionhttps://t.co/ojCDeivKzC
— Nature Medicine (@NatureMedicine) August 25, 2022
RCT | Nivolumab vs. nivolumab plus docetaxel for previously treated advanced or recurrent immune checkpoint inhibitor-naïve non-small-cell lung cancer.
25 Aug, 2022 | 11:48h | UTC
M-A | Erlotinib plus bevacizumab vs. erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer.
22 Aug, 2022 | 12:04h | UTC
RCT | Chest CT scan plus x-ray vs. chest x-ray for the follow-up of completely resected non-small-cell lung cancer.
16 Aug, 2022 | 13:50h | UTCChest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Totally unexpected! After resection of early NSCLC in 1775 pts, follow-up by ct-scan did not improve survival vs a simple chest X-Rays! We should ALWAYS questioned our practice. Amazing work from Virginie Westeel @barlesi @IFCTlung https://t.co/iMFGtpkQcF
— Benjamin Besse (@BenjaminBesseMD) August 12, 2022
Long-term results of a RCT | Gefitinib-alone vs. Gefitinib plus chemotherapy for non–small-cell lung cancer with mutated EGFR.
15 Aug, 2022 | 11:44h | UTC
RCT | Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus.
9 Aug, 2022 | 12:24h | UTCCommentary: Esophagus-Sparing Radiation Fails QOL Test in Lung Cancer— Esophageal-specific quality of life no better, but treatment reduced symptomatic esophagitis – MedPage Today (free registration required)
Commentary on Twitter
PROACTIVE was a phase 3 RCT of 90 pts with incurable lung cancer treated with esophageal sparing IMRT vs. standard palliative RT. ES-IMRT did not improve FACT-E ECS quality of life scores at 2wks but reduced grade≥2 esophagitis (24% vs. 2%). https://t.co/ExIp22WBPe #RadOnc #LCSM pic.twitter.com/lX8lD4Duja
— JAMA Oncology (@JAMAOnc) February 24, 2022
Systematic Review | Impact of low‐dose computed tomography screening on lung cancer‐related mortality.
8 Aug, 2022 | 11:52h | UTCSummary: Impact of computed tomography (CT) on lung cancer screening – Cochrane Library
Related:
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.
RCT | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy.
3 Aug, 2022 | 14:02h | UTCSintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Sintilimab plus #bevacizumab #biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell #lungcancer #NSCLC who progressed on EGFR TKI therapy: first interim results from ORIENT-31 https://t.co/5VwmLCcGW5 pic.twitter.com/RWeeyfuC6i
— The Lancet Oncology (@TheLancetOncol) August 2, 2022
M-A | Lung cancer occurrence after an episode of tuberculosis.
29 Jul, 2022 | 12:28h | UTC
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.
22 Jul, 2022 | 11:07h | UTC
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation.
15 Jul, 2022 | 12:55h | UTCA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation – Journal of Thoracic Disease
Part 1 – A guide to decision-making
Part 2 – Systematic review of evidence regarding resection extent in generally healthy patients
Part 3 – Systematic review of evidence regarding surgery in compromised patients or specific tumors
Part 4 – Systematic review of evidence involving SBRT and ablation
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer with driver alterations.
12 Jul, 2022 | 12:46h | UTC
Commentary on Twitter
Just published in #JCO: 🫁 Updated recommendations on therapy for stage IV #NSCLC with driver alterations by @ns_chd et al 👉 https://t.co/JzrxEey4Si #lungcancer #lcsm pic.twitter.com/CFPTJIkrhK
— Journal of Clinical Oncology (@JCO_ASCO) July 11, 2022
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer without driver alterations.
12 Jul, 2022 | 12:44h | UTC
Commentary on Twitter
Now available in #JCO: Key updated first-line recommendations on therapy for stage IV #NSCLC 🫁 without driver alterations by @ns_chd et al. ➡️ https://t.co/KovrwEtYGz #lungcancer #lcsm pic.twitter.com/iQONRkgxsj
— Journal of Clinical Oncology (@JCO_ASCO) July 11, 2022
Cohort Study | Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.
11 Jul, 2022 | 11:53h | UTCAuthor Interview: High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade – JAMA
Commentaries:
Tumor mutational burden ‘valuable biomarker’ for ICI response in NSCLC – medwire News
Commentary on Twitter
Very high levels of tumor mutational burden (TMB) are associated with benefit from #immunotherapy in NSCLC across PD-L1 expression levels and increased CD8+ T cells infiltration. https://t.co/qbq00ZzjFO #LCSM
— JAMA Oncology (@JAMAOnc) June 22, 2022
Guideline | Malignancy risk stratification for solitary pulmonary nodule.
4 Jul, 2022 | 12:33h | UTCSingle-arm phase II study: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
24 Jun, 2022 | 10:49h | UTCEZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
RCT: Furmonertinib vs. gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer.
9 Jun, 2022 | 10:25h | UTCFurmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
#ASCO22 – Phase 2 single-arm study: Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation.
6 Jun, 2022 | 11:15h | UTCAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute
#ASCO22 – Phase II RCT: Ramucirumab and pembrolizumab vs. standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy.
6 Jun, 2022 | 11:14h | UTCCommentary: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network
Commentary on Twitter
https://twitter.com/JCO_ASCO/status/1532785457947414531